We would love to hear your thoughts about our site and services, please take our survey here.
If you missed the #POLB CEO's recent presentation at the @DDWJournal webinar on "Using #AI to unlock the power of viral human challenge trial data", you can watch the full recording here:
https://m.youtube.com/watch?v=L11cwWRPl9Y
🕐#POLB presentation: 32:11 - 48:04
A plants beauty lies in its leaves, but its strength lies in its roots.
“…I am excited to be buying more OCT personally. Given the recent Phase I results, the Company appears to me to be significantly undervalued. It is for this reason that I, along with other shareholders and employees of Kingsley, have chosen to increase our direct holding in the business…”
https://total-market-solutions.com/2023/10/oxford-cannabinoid-technologies-plc-3/
A reminder that the #POLB CEO will be presenting at a @ShareSocUK #webinar on 25 Oct at 5pm.
Join to more about #POLB and their latest updates.
Register below :
https://www.sharesoc.org/events/sharesoc-webinar-with-poolbeg-pharma-polb25-oct-2023/
Kingsley Capital Partners LLP has sold 39,464,286 shares in the Company to Shareholders of Kingsley and has transferred 15,400,000 shares in the Company to employees of Kingsley.
Important this. It enables a number of investors who have long been part of the OCT story to be able to express their support for the business as individual shareholders. It clearly is a sign of growing confidence in OCT that investors want personally to become a part of the journey following last week’s Phase I announcement. Kingsley continues to be the largest shareholder in OCT.
Neil Mahapatra, Non-Executive Director of OCT and Managing Partner of Kingsley Capital Partners LLP, said:
“I am excited to be buying more into OCT personally. Given the recent Phase I results, the Company appears to me to be significantly undervalued. It is for this reason that I, along with other shareholders and employees of Kingsley, have chosen to increase our direct holding in the business.”
“…BAM is the key project. It’s essential to us to move that project forward. It’s the one with the best resource, the largest resource, the most potential for expansion as well. BAM is the priority…”
https://total-market-solutions.com/2023/10/landore-resources-ltd-october-2023/
“…They’re not all polymetallic. There’s a lot of silver and gold, and antimony and lithium and all sorts of other deposits that are just completely untouched…”
https://total-market-solutions.com/2023/10/vast-resources-plc-october-2023/
“…We have networks so we are in a good position to identify and acquire new projects. We are constantly reviewing opportunities with very strict criteria…”
https://total-market-solutions.com/2023/10/altona-rare-earths-plc-oct-2023/
Please see Vox & Proactive interviews following the release of today’s RNS:
https://twitter.com/PoolbegPharma/status/1714175552251142252
https://www.voxmarkets.co.uk/articles/jeremy-skillington-of-poolbeg-pharma-discusses-their-nasdaq-partnership-for-development-581b7af/
#POLB signed a strategic collaboration agreement with a #Nasdaq listed #biopharma to develop an optimised #oraldrug for a metabolic condition using #POLB's licensed technology
They are optimistic that this can lead to a full licensing agreement!!
https://www.londonstockexchange.com/news-article/POLB/poolbeg-partners-with-a-nasdaq-listed-biopharma/16169180
“…I am taking 90 per cent of my remuneration in shares. We think the price of the shares are particularly distressed and we want to get in the trenches with the shareholders…”
https://total-market-solutions.com/2023/10/ecr-minerals-oct-2023/
“…Further exploration is underway, funded by the fresh revenue channels opened this summer. Production at the pilot plant continues to ramp up. And an off-take agreement may be not too far down the road…”
https://total-market-solutions.com/2023/10/andrada-mining-ltd/
“…Nevada is the top place in the world to explore and develop. Golden Metal Resources hosts the largest known, undeveloped, tungsten resource in the US. With tungsten on the US’s critical minerals list there’s grants out there for explorers…”
https://total-market-solutions.com/2023/10/golden-metal-resources-plc-october/
Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. Through opportunistic identification of assets which complement Poolbeg's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets. With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.
Https://twitter.com/PoolbegPharma/status/1711260201095983330
Insightful article on how #AI can help to speed up #drugdiscovery.
The high quality & unique nature of human challenge trial data can power AI-enabled #drugdiscovery to identify novel & unlock meaningful insights into human disease
https://www.nature.com/articles/d41586-023-02896-9
Pneumagen have announced the positive challenge trial results for their broad-spectrum antiviral candidate Neumifil. This is fantastic news for #HVO as it is yet another example of the value of the human challenge trials in delivering clinical efficacy data and de-risking later clinical development.
Human challenge have immense potential for growth among biotech companies, as the cost‐effective human efficacy data generated by human challenge trials becomes increasingly appealing in a tight funding environment. Positive efficacy data can significantly boost the value of an asset, which can be transformative for biotechs. Additionally, challenge trial data can accelerate time‐to‐market for vaccines and antivirals by up to three years, enabling biopharma companies to maximise revenues for their products whilst their patents are active.
Link to RNS below :
https://polaris.brighterir.com/public/hvivo/news/rns/story/wkj1qor
An interview featuring Jeremy Skillington and Emily Liu, following her industry piece on AI:
https://www.youtube.com/watch?v=TWl5aCf-seo
“…With cash in hand, a new venture in a growing market, and an ambitious management team that has proven its ability to identify and develop a growth business, LETS seems an intriguing prospect – especially with a share price of just 2.65p and a market cap of £5m. With a seasonal product likely to generate a Q4 revenues boost, LETS promises to be a microcap worth watching over the coming months…”
https://total-market-solutions.com/2023/10/lets-explore-group-plc/